Reaction #1255288

ord-b0fc7084691d42c0aa052f0f232efca3

Conditions

Detailed conditions
See reaction.notes.procedure_details.

Workup

  1. 1
    Otherreacted for 3 hours under a stream of nitrogen gas
  2. 2
    OtherAnd then, reaction product
  3. 3
    Otherwas precipitated
  4. 4
    workup.ADDITIONby adding cold diethylether
  5. 5
    Filtrationfiltered on a filter paper
  6. 6
    Otherdried under a reduced pressure
  7. 7
    workup.DISSOLUTIONAfter dissolving
  8. 8
    Other0.25 g of dried reaction product in 7.5 ml of dimethylformamide
  9. 9
    Otherreacted at room temperature for 24 hours under a nitrogen gas

Procedure

3 g of mPEG-PLGA obtained above and 80 mg of p-nitrofluoroformate, a linker compound, were dissolved in 30 ml of methylene chloride. Then, 63 mg of pyridine was added to the solution, and reacted for 3 hours under a stream of nitrogen gas. And then, reaction product was precipitated by adding cold diethylether, filtered on a filter paper and dried under a reduced pressure. After dissolving 0.25 g of dried reaction product in 7.5 ml of dimethylformamide, 10 mg of doxorubicin-HCl(Sigma Chem. Co., U.S.A.) and 6.75 mg of triethylamine were added and reacted at room temperature for 24 hours under a nitrogen gas to obtain doxorubicin-conjugated micelle monomer(see: FIG. 2). The said micelle monomers were dispersed in 300 ml of triple distilled water to form doxorubicin-conjugated sustained release micelles, and free doxorubicin was removed by dialyzing the mixture 5 times against 3 L of triple distilled water each time. Doxorubicin-conjugated sustained release micelles were pelletized by ultracentrifugation, and freeze-dried after removing supernatant, and then, stored in the form of doxorubicin-conjugated micelle monomer.

Source

DOI: 10.6084/m9.figshare.5104873.v1Patent: US06623729B2uspto-grants-2003_09